BioNTech news - the latest biotech news from Labiotech.eu

Home BioNTech Page 5

Latest Posts

bacteria neutrophil immune response RNA

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

interview sean marett biontech2

News and Trends 12 Nov 2015

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field… We first interviewed Sean Marett, COO of BioNTech. This German Biotech is the largest private Biotech in EU and so far counts over 400 employees…BioNTech also recently signed […]

November 12, 2015 - 1 minutemin - By Philip Hemme

lightning bolt biotech

News and Trends 7 Nov 2015

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Monday: The French Scientist Who Also ‘Discovered’ CRISPR is Finally Recognized with a Prize too Tuesday: €100 Million Investment Round Prepares CureVac For Vaccine Expansion Wednesday: €1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech Thursday: Damn, that was BIO-Europe 2015 in Munich! Friday: Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on […]

November 7, 2015 - 1 minutemin - By Philip Hemme

biontech sanofi mrna immunooncology

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

BioNTech Eli Lilly

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

Immatics optimiert

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

ADVERTISEMENT

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

ADVERTISEMENT